CVS 10-Q Quarterly Report March 31, 2023

CVS HEALTH CORP

10-Ks and 10-Qs

10-Q	Quarter ended Sept. 30, 2024
10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-Q	Quarter ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-Q	Quarter ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-Q	Quarter ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-Q	Quarter ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-Q	Quarter ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-Q	Quarter ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-K	Fiscal year ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-Q	Quarter ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-K	Fiscal year ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on April 5, 2024
DEF 14A	Filed on April 7, 2023
DEF 14A	Filed on April 1, 2022
DEF 14A	Filed on April 2, 2021
DEF 14A	Filed on April 3, 2020
DEF 14A	Filed on April 5, 2019
DEF 14A	Filed on April 24, 2018
DEF 14A	Filed on March 31, 2017
DEF 14A	Filed on April 8, 2016
DEF 14A	Filed on Aug. 5, 2015
DEF 14A	Filed on March 27, 2015
DEF 14A	Filed on March 28, 2014
DEF 14A	Filed on March 29, 2013
DEF 14A	Filed on March 26, 2012
DEF 14A	Filed on March 30, 2011
DEF 14A	Filed on March 29, 2010

TABLE OF CONTENTS

Part I Item 1. Financial Statements Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of Operations ( Md&a )Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures Part Ii.other Information Part II Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered Sales Of Equity Securities and Use Of Proceeds Item 3. Defaults Upon Senior Securities Item 4. Mine Safety Disclosures Item 5. Other Information Item 6. Exhibits

Exhibits

2.1 Agreement and Plan of Merger, dated as of February 7, 2023, by and among CVS Pharmacy, Inc., Halo Merger Sub Corp., Oak Street Health, Inc. and, for the limited purposes set forth therein, CVS Health Corporation (incorporated by reference to Exhibit 2.1 to the Registrants Current Report on Form 8-K filed February 8, 2023). 4.1 Form of the Registrants 2026 Note (incorporated by reference to Exhibit 4.1 to the Registrants Current Report on Form 8-K filed on February 21, 2023). 4.2 Form of the Registrants 2030 Note (incorporated by reference to Exhibit 4.2 to the Registrants Current Report on Form 8-K filed on February 21, 2023). 4.3 Form of the Registrants 2033 Note (incorporated by reference to Exhibit 4.3 to the Registrants Current Report on Form 8-K filed on February 21, 2023). 4.4 Form of the Registrants 2053 Note (incorporated by reference to Exhibit 4.4 to the Registrants Current Report on Form 8-K filed on February 21, 2023). 10.1* Restrictive Covenant Agreement dated June 20, 2022 between the Registrant and Tilak Mandadi. 10.2* Change in Control Agreement effective as of August 11, 2022 between the Registrant and Tilak Mandadi. 10.3* Restrictive Covenant Agreement dated May 11, 2022 between the Registrant and Prem Shah. 10.4* Change in Control Agreement effective as of January 27, 2023 between the Registrant and Prem Shah. 10.5 Second Amendment to Five Year Credit Agreement dated as of March 23, 2023, to the Five Year Credit Agreement, dated as of May 16, 2019, as amended by the First Amendment to Five Year Credit Agreement, dated as of May 16, 2022, by and among the Registrant, the lenders party thereto and Bank of America N.A. as Administrative Agent. 10.6 Second Amendment to Five Year Credit Agreement dated as of March 23, 2023, to the Five Year Credit Agreement, dated as of May 11, 2021, as amended by the First Amendment to Five Year Credit Agreement, dated as of May 16, 2022, by and among the Registrant, the lenders party thereto and Bank of America N.A. as Administrative Agent. 10.7 First Amendment to Five Year Credit Agreement dated as of March 23, 2023, to the Five Year Credit Agreement, dated as of May 16, 2022, by and among the Registrant, the lenders party thereto and Bank of America N.A. as Administrative Agent. 10.8 Term Loan Agreement, dated May 1, 2023, by and among the Registrant, the lenders party thereto and Barclays Bank PLC, as administrative agent (incorporated by reference to Exhibit 10.1 to the Registrants Current Report on Form 8-K filed on May 2, 2023). 10.9 Form of Voting Agreement by and among CVS Pharmacy, Inc., certain stockholders of Oak Street Health, Inc. and certain members of the Oak Street Health, Inc. board of directors parties thereto (incorporated by reference to Exhibit 99.1 to the Registrants Current Report on Form 8-K filed February 8, 2023). 15.1 Letter from Ernst & Young LLP acknowledging awareness of the use of a report datedMay3, 2023related to their reviews of interim financial information. 31.1 Certification by the Chief Executive Officer. 31.2 Certification by the Chief Financial Officer. 32.1 Certification by the Chief Executive Officer. 32.2 Certification by the Chief Financial Officer.

Supplier name	Ticker
Johnson & Johnson	JNJ
The Procter & Gamble Company	PG
Pfizer Inc.	PFE
Merck & Co., Inc.	MRK
Abbott Laboratories	ABT
Thermo Fisher Scientific Inc.	TMO
AbbVie Inc.	ABBV
Danaher Corporation	DHR
Medtronic plc	MDT
Bristol-Myers Squibb Company	BMY
Eli Lilly and Company	LLY
Amgen Inc.	AMGN

CVS 10-Q Quarter ended March 31, 2023

Exhibits